Pacific Bio (PACB) Reports In-Line Q1 EPS, Achieves Second Development Milestone

Pacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

Pacific Biosciences of California, Inc. (Nasdaq: PACB), provider of the PacBio® RS II Sequencing System, today announced that it has achieved a second development milestone under its development, commercialization and license agreement with F. Hoffman-La Roche Ltd (Roche), earning an additional $10 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook
• Jefferies Upgrades Friedrich Vorwerk Group SE (VH2:GR) to Hold